MFA Launches MulteFire 1.0 Certification Program to Support Interoperable Device Ecosystem for Private Wireless Networks
19.11.2020 17:00:00 EET | Business Wire | Press release
The MulteFire Alliance (MFA) today announced the launch of its MulteFire 1.0 Certification Program. In addition, the first customer premise equipment (CPE) device has been certified compliant.
With MulteFire technology, organizations can now cost-effectively deploy their own private LTE network and realize the benefits of better capacity, coverage, mobility and built-in security needed for industry 4.0 use cases.
The MulteFire 1.0 specification defines LTE operation in unlicensed and shared spectrum bands, including the global 5 GHz band. The certification program tests eNodeBs together with UEs for conformance with the MulteFire 1.0 specification to ensure an interoperable, global device ecosystem for use in unlicensed or shared radio spectrum. By removing the need for licensed spectrum, MulteFire will help to lower entry cost and accelerate high-speed, secure private wireless networking deployment.
MulteFire technology opens up an entirely new range of private wireless use cases that add to existing deployment scenarios in asset-intensive industries. New opportunities include rapid deployment situations such as field hospitals and emergency response, as well as temporary systems for pop-up events, touring, cultural and sports programs. In addition, MulteFire can also be used to complement existing private wireless deployment in licensed spectrum, for example to add capacity by tapping into the large bandwidth available in the unlicensed 5 GHz spectrum band.
“The MulteFire 1.0 Certification Program is a significant milestone for the Alliance and represents the diligent efforts of our Certification Working Group to bring this program to the industry,” said Mazen Chmaytelli, president, MFA. “We are also excited to share that we have already certified the first MulteFire radio and device solutions from Nokia as compliant.”
“By enabling private wireless connectivity in unlicensed and shared spectrum, we enable even more enterprises to deploy their own private LTE and 5G networks,” said Stephan Litjens, General Manager, Nokia Digital Automation Cloud and MFA board chair. “As a founding member of MFA, we’re firmly at the forefront of this initiative – firstly with certification of our own MulteFire CPE offering – and also to accelerate a device ecosystem for the benefit of enterprise digital transformation.”
Through overlapping membership with 3GPP, the MFA is also supporting efforts for 5G NR standalone operation in unlicensed spectrum. A recent ABI Research white paper quantifies the total addressable market size for private network equipment (for industrial manufacturing, ports, logistics, mining, and energy) in LTE and 5G at $32.37B by 2030. ABI also states that by 2030 more than half of industry verticals’ private networks using LTE or 5G will be deployed in unlicensed, shared or dedicated licensed spectrum.
DEKRA Named Authorized Test Lab for MulteFire 1.0
DEKRA, an MFA member and leader in product certification, conducted the certification testing for MulteFire 1.0 and DEKRA Malaga has been named an Authorized Test Lab for the MulteFire 1.0 Certification Program. DEKRA was already named the first Authorized Test Lab for the MulteFire 1.9 GHz sXGP Certification Program launched in Japan at the end of 2019.
“DEKRA is very pleased to continue its partnership with the MFA with the addition of MulteFire 1.0 testing to our services offering, and we are happy to contribute to the success of the MulteFire ecosystem,” said Andrés Moreno, Managing Director, DEKRA Testing and Certification Spain.
The MFA Certification Program is available to all MFA members. Upon device certification, companies will receive the ‘MulteFire Certified’ logo and certification mark for product promotion and marketing purposes. The MFA welcomes membership from all companies that have an interest in private wireless networks. To join the MFA and for more details on membership levels, visit www.multefire.org/join.
For more information on the MFA Certification Program, visit www.multefire.org/certification-program/.
Resources:
- ABI Research White Paper: The Importance of Spectrum Liberalization for Private 5G Networks
- Blog: MulteFire 1.0 Regulatory Analysis White Paper Now Available to MFA Members
- Webpage: Certification FAQ
About the MFA
The MFA is an international association dedicated to building a global ecosystem in support of the common interests of members, developers and users in the application of Long Term Evolution (LTE) and next-generation mobile cellular technology, such as 5G New Radio, in configurations that use unlicensed or shared radio spectrum. For more information about MulteFire technology, its benefits, or how to become a member of the MFA, visit www.MulteFire.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005382/en/
Contact information
MulteFire Alliance
Lori Mesecke, +1-503-459-9150
press@multefire.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom